[High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases]

Fifty patients with advanced breast cancer were treated by high dose cisplatin (DDP) combination chemotherapy during the period of August 1984 to June 1991. All of them had measurable disease. Among the fifty patients, 24 had previously received chemotherapy. DDP was given at a dose of 50-128 mg/m2 intravenously every 3 weeks. The regimen was PCMF (DDP + CTX + MTX + 5FU), PA (DDP+ADM) +/- other agents or PF (DDP + 5FU) +/- other agents. The overall response rate was 76% (38/50) with a CR rate of 20% (10/50). The median response duration and median survival time were 5.5 months and 15 months, respectively. Best response was obtained in soft tissue metastasis (83.3%, 40/48), and in lung metastasis (79.3%, 23/29). The response rate was lower in liver metastasis (40%, 2/5) and lowest in bone metastasis (0/9). Marked gastrointestinal reaction was observed in most patients (84%). These results indicate that high dose cisplatin combination chemotherapy is an effective regimen for advanced breast cancer.